New Drug Approval for Lasmiditan: A New Approach to
Cassandra Kuhn and Olivia Reiber
Millions of people worldwide suffer from migraines, and current treatment may not be suitable for all patients. Patients who have cardiovascular risk factors as well as migraines are not able to take triptans, which are the mainstay of acute migraine treatment, because triptasns can cause an increase in blood pressure and potentially cause an unwanted cardiovascular event. Lasmiditan (Reyvow™) is a newly FDA-approved drug that is indicated for acute treatment of migraine with or without aura in adults that is safe for patients who have cardiovascular risk factors. This new drug gives hope to many patients who have untreated migraine pain and has the potential to greatly change the current treatment guidelines for migraines.